Spoken Alpha
Scinai Immunotherapeutics Ltd.
BiondVax Pharmaceuticals Ltd. develops nanosized antibodies (NanoAbs) for treating infectious and autoimmune diseases, including COVID-19, psoriasis, psoriatic arthritis, and asthma.
Scinai Immunotherapeutics Ltd is a Healthcare company operating in Biotechnology with a $1.1M market cap.
Most recent reported earnings: Q2 FY2026 (Aug 23, 2026).
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for SCNI.
$ curl https://api.spokenalpha.com/v1/companies/SCNIFAQ
Spoken Alpha indexes SCNI's earnings call transcripts at https://spokenalpha.com/companies/SCNI. Each call links to attributed speakers and parsed analyst Q&A. Scinai Immunotherapeutics Ltd.'s own investor relations page is at https://www.scinai.com/investorsrelations.
Scinai Immunotherapeutics Ltd. (SCNI) held its most recent earnings call on 2024-08-20, covering fiscal Q2 2024.
Scinai Immunotherapeutics Ltd. (SCNI) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-23 | $-0.74 | — | — | $467.9K | — | — | EODHD |
| Q1 FY2026 | 2026-06-09 | $0.94 | — | — | $487.7K | — | — | EODHD |
| Q3 FY2025 | 2025-11-27 | $-24.85 | — | — | $269.0K | — | — | EODHD |
| Q2 FY2025 | 2025-09-01 | $-2.60 | $0.00 | — | $386.5K | — | — | EODHD |
| Q1 FY2025 | 2025-05-06 | $4.31 | $0.00 | — | $586.0K | — | — | EODHD |
| Q4 FY2024 | 2025-02-25 | $-26.35 | — | — | $206.0K | — | — | EODHD |
| Q3 FY2024 | 2024-11-21 | $12.39 | — | — | $168.0K | — | — | EODHD |
| Q2 FY2024 | 2024-07-01 | $-4.31 | — | — | $284.0K | — | — | EODHD |
| Q1 FY2024 | 2024-05-14 | $-24.00 | $-6.20 | -100.0% | $0 | — | — | EODHD |
| Q4 FY2023 | 2023-12-30 | $-240.00 | $-62.00 | -100.0% | $0 | — | — | EODHD |
| Q3 FY2023 | 2023-10-30 | $8.00 | $-9.40 | +100.0% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-10 | $-12.00 | $-9.10 | -31.9% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-14 | $-12.00 | $-7.30 | -64.4% | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-11-29 | $0.29 | $-1.00 | +100.0% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-24 | $-0.61 | $-1.00 | +39.0% | — | — | — | EODHD |
| Q1 FY2022 | 2022-05-31 | $-23.93 | $-10.00 | -100.0% | — | — | — | EODHD |
| Q4 FY2021 | 2022-03-27 | $0.01 | $-0.16 | +100.0% | — | — | — | EODHD |
| Q3 FY2021 | 2021-11-29 | $-0.01 | — | — | — | — | — | EODHD |
| Q2 FY2021 | 2021-08-25 | $-0.01 | — | — | — | — | — | EODHD |
| Q1 FY2021 | 2021-05-12 | $-1.14 | $-0.01 | -100.0% | — | — | — | EODHD |
Source: EODHD. SCNI reported actuals as published; sparse fields render as —.